
Krystal Biotech, Inc.: shareholders and insiders
Price
$315.11
November 19, 2026Market cap $9.2B
What Ploutos Investor adds for Krystal Biotech
Part of Ploutos Investor, €9.99 a month
- The full history: 5 fiscal years, from 2021
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 19, 2025 to Nov 13, 2026, from their own Form 4 filings.
Bought on the market
–
nobody
Sold on the market
$101M
6 people
From Nov 19, 2025 to Nov 19, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan87%
- The rest13%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 19, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·no buys·sold $83M by 6 people
- 2025: no buys, sold $17M by 2 people
- 2026: no buys, sold $83M by 6 people
- Nov 12, 2026Dino A RossiDirectorKind
- Sep 4, 2026Suma KrishnanPresident, R&DKind10b5-1
- Sep 4, 2026Suma KrishnanPresident, R&DKind10b5-1
- Sep 4, 2026Suma KrishnanPresident, R&DKind10b5-1
- Sep 4, 2026Suma KrishnanPresident, R&DKind10b5-1
- Sep 4, 2026Suma KrishnanPresident, R&DKind10b5-1
- Sep 4, 2026Suma KrishnanPresident, R&DKind10b5-1
- Sep 4, 2026Suma KrishnanPresident, R&DKind10b5-1
- Sep 4, 2026Suma KrishnanPresident, R&DKind10b5-1
- Sep 4, 2026Suma KrishnanPresident, R&DKind10b5-1
- Sep 4, 2026Suma KrishnanPresident, R&DKind10b5-1
- Sep 4, 2026Suma KrishnanPresident, R&DKind10b5-1
- Sep 4, 2026Suma KrishnanPresident, R&DKind10b5-1
- Sep 4, 2026Suma KrishnanPresident, R&DKind10b5-1
- Sep 4, 2026Krish S KrishnanPresident and CEOKind10b5-1
- Sep 4, 2026Krish S KrishnanPresident and CEOKind10b5-1
- Sep 4, 2026Krish S KrishnanPresident and CEOKind10b5-1
- Sep 4, 2026Krish S KrishnanPresident and CEOKind10b5-1
- Sep 4, 2026Krish S KrishnanPresident and CEOKind10b5-1
- Sep 4, 2026Krish S KrishnanPresident and CEOKind10b5-1
- Sep 4, 2026Krish S KrishnanPresident and CEOKind10b5-1
- Sep 4, 2026Krish S KrishnanPresident and CEOKind10b5-1
- Sep 4, 2026Krish S KrishnanPresident and CEOKind10b5-1
- Sep 4, 2026Krish S KrishnanPresident and CEOKind10b5-1
- Sep 4, 2026Krish S KrishnanPresident and CEOKind10b5-1
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 12, 2026 | Dino A RossiDirector | 3,500 | – | – | Form 4 | |
| Sep 4, 2026 | Suma KrishnanPresident, R&D | 10b5-1 | 520 | $354.54 | $184.4K | Form 4 |
| Sep 4, 2026 | Suma KrishnanPresident, R&D | 10b5-1 | 2,006 | $355.57 | $713.3K | Form 4 |
| Sep 4, 2026 | Suma KrishnanPresident, R&D | 10b5-1 | 3,267 | $356.37 | $1.2M | Form 4 |
| Sep 4, 2026 | Suma KrishnanPresident, R&D | 10b5-1 | 3,962 | $357.57 | $1.4M | Form 4 |
| Sep 4, 2026 | Suma KrishnanPresident, R&D | 10b5-1 | 3,180 | $358.42 | $1.1M | Form 4 |
| Sep 4, 2026 | Suma KrishnanPresident, R&D | 10b5-1 | 3,392 | $359.39 | $1.2M | Form 4 |
| Sep 4, 2026 | Suma KrishnanPresident, R&D | 10b5-1 | 2,320 | $360.47 | $836.3K | Form 4 |
| Sep 4, 2026 | Suma KrishnanPresident, R&D | 10b5-1 | 1,242 | $361.61 | $449.1K | Form 4 |
| Sep 4, 2026 | Suma KrishnanPresident, R&D | 10b5-1 | 1,992 | $362.65 | $722.4K | Form 4 |
| Sep 4, 2026 | Suma KrishnanPresident, R&D | 10b5-1 | 565 | $363.34 | $205.3K | Form 4 |
| Sep 4, 2026 | Suma KrishnanPresident, R&D | 10b5-1 | 1,329 | $364.48 | $484.4K | Form 4 |
| Sep 4, 2026 | Suma KrishnanPresident, R&D | 10b5-1 | 826 | $365.41 | $301.8K | Form 4 |
| Sep 4, 2026 | Suma KrishnanPresident, R&D | 10b5-1 | 399 | $366.56 | $146.3K | Form 4 |
| Sep 4, 2026 | Krish S KrishnanPresident and CEO | 10b5-1 | 520 | $354.54 | $184.4K | Form 4 |
| Sep 4, 2026 | Krish S KrishnanPresident and CEO | 10b5-1 | 2,029 | $355.57 | $721.5K | Form 4 |
| Sep 4, 2026 | Krish S KrishnanPresident and CEO | 10b5-1 | 3,297 | $356.37 | $1.2M | Form 4 |
| Sep 4, 2026 | Krish S KrishnanPresident and CEO | 10b5-1 | 3,981 | $357.57 | $1.4M | Form 4 |
| Sep 4, 2026 | Krish S KrishnanPresident and CEO | 10b5-1 | 3,143 | $358.42 | $1.1M | Form 4 |
| Sep 4, 2026 | Krish S KrishnanPresident and CEO | 10b5-1 | 3,357 | $359.39 | $1.2M | Form 4 |
| Sep 4, 2026 | Krish S KrishnanPresident and CEO | 10b5-1 | 2,266 | $360.46 | $816.8K | Form 4 |
| Sep 4, 2026 | Krish S KrishnanPresident and CEO | 10b5-1 | 1,214 | $361.61 | $439.0K | Form 4 |
| Sep 4, 2026 | Krish S KrishnanPresident and CEO | 10b5-1 | 2,010 | $362.65 | $728.9K | Form 4 |
| Sep 4, 2026 | Krish S KrishnanPresident and CEO | 10b5-1 | 573 | $363.34 | $208.2K | Form 4 |
| Sep 4, 2026 | Krish S KrishnanPresident and CEO | 10b5-1 | 1,358 | $364.48 | $495.0K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before May 27, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by KRYS's officers and directors from 2017 up to November 18, 2025, 9 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 4 more, back to 2017
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
Fell to 5% or less (3)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Bridgewater (Dalio)In the quarter+83%
- Renaissance TechnologiesIn the quarter+5.8%
- Citadel Advisors (Griffin)In the quarter×16.3
- AQR CapitalIn the quarter+34%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Bridgewater (Dalio) | 99.9K | +83% | $33M | 0.14% |
| Renaissance Technologies | 63.1K | +5.8% | $21M | 0.03% |
| Citadel Advisors (Griffin) | 44.5K | ×16.3 | $15M | 0.01% |
| AQR Capital | 18.8K | +34% | $6.2M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 10.0% of its shares outstanding were held short, -15.5% since the report before.
- Shares held short
- 2.94M
- 10.0%
- Since the report before3.48M on Sep 30, 2026
- -15.5%
- 10.3
- 284.2K
- More days to cover thanof 4,578 US-listed companies with enough volume
- 92%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 2.10M
- Nov 15, 2023: Shares held short 2.07M
- Nov 30, 2023: Shares held short 2.12M
- Dec 15, 2023: Shares held short 1.95M
- Dec 29, 2023: Shares held short 2.17M
- Jan 12, 2024: Shares held short 1.97M
- Jan 31, 2024: Shares held short 2.03M
- Feb 15, 2024: Shares held short 2.47M
- Feb 29, 2024: Shares held short 2.51M
- Mar 15, 2024: Shares held short 2.24M
- Mar 28, 2024: Shares held short 2.17M
- Apr 15, 2024: Shares held short 2.45M
- Apr 30, 2024: Shares held short 2.59M
- May 15, 2024: Shares held short 2.81M
- May 31, 2024: Shares held short 2.69M
- Jun 14, 2024: Shares held short 2.90M
- Jun 28, 2024: Shares held short 3.51M
- Jul 15, 2024: Shares held short 3.67M
- Jul 31, 2024: Shares held short 3.50M
- Aug 15, 2024: Shares held short 3.54M
- Aug 30, 2024: Shares held short 3.69M
- Sep 13, 2024: Shares held short 3.67M
- Sep 30, 2024: Shares held short 3.52M
- Oct 15, 2024: Shares held short 3.54M
- Oct 31, 2024: Shares held short 3.45M
- Nov 15, 2024: Shares held short 3.60M
- Nov 29, 2024: Shares held short 3.65M
- Dec 13, 2024: Shares held short 3.70M
- Dec 31, 2024: Shares held short 3.37M
- Jan 15, 2025: Shares held short 3.25M
- Jan 31, 2025: Shares held short 3.01M
- Feb 14, 2025: Shares held short 3.19M
- Feb 28, 2025: Shares held short 2.76M
- Mar 14, 2025: Shares held short 2.70M
- Mar 31, 2025: Shares held short 2.71M
- Apr 15, 2025: Shares held short 2.42M
- Apr 30, 2025: Shares held short 2.37M
- May 15, 2025: Shares held short 2.60M
- May 30, 2025: Shares held short 2.92M
- Jun 13, 2025: Shares held short 3.03M
- Jun 30, 2025: Shares held short 3.18M
- Jul 15, 2025: Shares held short 3.14M
- Jul 31, 2025: Shares held short 3.40M
- Aug 15, 2025: Shares held short 3.48M
- Aug 29, 2025: Shares held short 3.45M
- Sep 15, 2025: Shares held short 3.60M
- Sep 30, 2025: Shares held short 3.40M
- Oct 15, 2025: Shares held short 2.89M
- Oct 31, 2025: Shares held short 2.88M
- Nov 14, 2025: Shares held short 2.87M
- Nov 28, 2025: Shares held short 2.87M
- Dec 15, 2025: Shares held short 2.72M
- Dec 31, 2025: Shares held short 2.68M
- Jan 15, 2026: Shares held short 2.66M
- Jan 30, 2026: Shares held short 2.71M
- Feb 13, 2026: Shares held short 2.76M
- Feb 27, 2026: Shares held short 2.95M
- Mar 13, 2026: Shares held short 2.89M
- Mar 31, 2026: Shares held short 3.14M
- Apr 15, 2026: Shares held short 2.91M
- Apr 30, 2026: Shares held short 3.10M
- May 15, 2026: Shares held short 3.18M
- May 29, 2026: Shares held short 3.15M
- Jun 15, 2026: Shares held short 3.14M
- Jun 30, 2026: Shares held short 3.52M
- Jul 15, 2026: Shares held short 3.50M
- Jul 31, 2026: Shares held short 3.20M
- Aug 14, 2026: Shares held short 3.20M
- Aug 31, 2026: Shares held short 3.35M
- Sep 15, 2026: Shares held short 3.16M
- Sep 30, 2026: Shares held short 3.48M
- Oct 15, 2026: Shares held short 2.94M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading81.8% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 81.8% of the shares in the reported trades were short sales, against 67.7% in the 14 before.
- Last 14 sessionsOct 30, 2026 – Nov 18, 2026
- 81.8%
- The 14 beforeOct 12, 2026 – Oct 29, 2026
- 67.7%
- Change
- +14.1 pts
- Short sales a dayon average, of 116.0K shares
- 94.9K
- More than atof 3,656 US-listed companies, same days
- 100%
- Median of alleight in ten from 34.4% to 63.7%
- 50.3%
- Short sales
- Oct 12, 2026: Short sales 90.5%
- Oct 13, 2026: Short sales 69.9%
- Oct 14, 2026: Short sales 74.7%
- Oct 15, 2026: Short sales 80%
- Oct 16, 2026: Short sales 79.5%
- Oct 19, 2026: Short sales 63.9%
- Oct 20, 2026: Short sales 72.9%
- Oct 21, 2026: Short sales 56.3%
- Oct 22, 2026: Short sales 65.9%
- Oct 23, 2026: Short sales 63.3%
- Oct 26, 2026: Short sales 58.4%
- Oct 27, 2026: Short sales 70.8%
- Oct 28, 2026: Short sales 55.3%
- Oct 29, 2026: Short sales 75.4%
- Oct 30, 2026: Short sales 80.4%
- Nov 2, 2026: Short sales 83.6%
- Nov 3, 2026: Short sales 79.9%
- Nov 4, 2026: Short sales 87.9%
- Nov 5, 2026: Short sales 83.7%
- Nov 6, 2026: Short sales 88.2%
- Nov 9, 2026: Short sales 79.1%
- Nov 10, 2026: Short sales 76.8%
- Nov 11, 2026: Short sales 78.6%
- Nov 12, 2026: Short sales 84.2%
- Nov 13, 2026: Short sales 73.1%
- Nov 16, 2026: Short sales 83.8%
- Nov 17, 2026: Short sales 71.8%
- Nov 18, 2026: Short sales 75.4%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Suma KrishnanPresident, R&DDirectly1.32M
- Krish S KrishnanPresident and CEODirectly1.35M
- Daniel JanneyDirectorDirectly743
- Dino A RossiDirectorDirectly46.5K
- Kathryn RomanoChief Accounting OfficerDirectly22.4K
- John Charles ThomasEVP, General CounselDirectly–
- Julian S GangolliDirectorDirectly–
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Suma KrishnanPresident, R&D | 1.32M | 1.48M | Sep 4, 2026 | Form 4 |
| Krish S KrishnanPresident and CEO | 1.35M | 1.41M | Sep 4, 2026 | Form 4 |
| Daniel JanneyDirector | 743 | 75.7K | Feb 27, 2026 | Form 4 |
| Dino A RossiDirector | 46.5K | – | Nov 12, 2026 | Form 4 |
| Kathryn RomanoChief Accounting Officer | 22.4K | – | Mar 2, 2026 | Form 4 |
| John Charles ThomasEVP, General Counsel | – | – | Jun 25, 2026 | Form 4 |
| Julian S GangolliDirector | – | – | May 20, 2024 | Form 4 |
A lower bound: it counts only the 7 officers and directors with a market trade since Nov 20, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- XBIState Street(R) SPDR(R) S&P(R) Biotech ETFWeight in the fund1.10%
- IJTiShares S&P Small-Cap 600 Growth ETFWeight in the fund1.07%
- IBBiShares Biotechnology ETFWeight in the fund0.75%
- LABUDirexion Daily S&P Biotech Bull 3X SharesWeight in the fund0.75%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.58%
- SPSMState Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETFWeight in the fund0.53%
- IJRiShares Core S&P Small-Cap ETFWeight in the fund0.53%
- IWMiShares Russell 2000 ETFWeight in the fund0.30%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.30%
- VBKVanguard Small-Cap Growth Index FundWeight in the fund0.29%
26 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 286
- Q4 2025: Managers 335
- Q1 2026: Managers 370
- Q2 2026: Managers 422
Institutional investors by quarter
The fund managers holding KRYS, quarter by quarter, from Q3 2017 to Q2 2025, 32 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 422 managers held 30.30M shares, worth $11.0B. During the quarter 93 opened a position, 41 closed one, 170 added and 109 trimmed.
The largest holders, Q2 2026
- FMRIn the quarter+1.0%
- BlackRockIn the quarter+6.1%
- Avoro Capital AdvisorsIn the quarter
- Vanguard Portfolio ManagementIn the quarter+8.1%
- State StreetIn the quarter+2.8%
- Vanguard Capital ManagementIn the quarter+6.5%
- Soleus Capital ManagementIn the quarter-19%
- Capital World InvestorsIn the quarter-5.7%
- Vestor CapitalIn the quarter×3,505
- Geode Capital ManagementIn the quarter+8.5%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| FMR | 4.42M | +1.0% | $1.6B |
| BlackRock | 4.18M | +6.1% | $1.6B |
| Avoro Capital Advisors | 2.89M | $1.1B | |
| Vanguard Portfolio Management | 1.57M | +8.1% | $585M |
| State Street | 1.35M | +2.8% | $502M |
| Vanguard Capital Management | 1.24M | +6.5% | $461M |
| Soleus Capital Management | 939.3K | -19% | $349M |
| Capital World Investors | 777.8K | -5.7% | $289M |
| Vestor Capital | 700.9K | ×3,505 | $78.2K |
| Geode Capital Management | 699.0K | +8.5% | $260M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Krystal Biotech's filings show?
Who buys and sells is one part of Krystal Biotech's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have KRYS's insiders bought or sold?
From May 27, 2026 to Nov 13, 2026 Krystal Biotech's insiders bought 0 and sold $42M of shares on the market. 80% of the sales were under set 10b5-1 plans.
Which well-known managers hold KRYS?
4 of the managers we track held the shares on Sep 30, 2026. The largest position was Bridgewater (Dalio)'s, worth $33M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.